Can a new PET tracer light up Alzheimer's plaques in the living brain?
Diagnosis
Recruiting now
This phase III trial is evaluating whether an experimental PET imaging agent, [18F]Fluorbetazine, can accurately detect amyloid-beta plaques in the brain—a hallmark of Alzheimer's disease. The study will include about 400 adults aged 40 and older with normal cognitive function, m…
Phase: PHASE3 • Sponsor: HTA Co., Ltd. • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC